Yunqi Capital Leads Exclusive Pre-A Round in Kongshan Ci Technology, Accelerating Brain-Computer Interface Commercialization | Yunqi Capital

As the connection between humans and machines gets redefined, brain-computer interfaces represent one of the more imaginative frontiers. And as scientific exploration reaches the critical stage of delivering real clinical value, the "non-invasive pathway" is emerging as one of the more scalable directions.

Recently, Yunqi Capital led the exclusive Pre-A round for Kongshanci Technology, a company focused on non-invasive brain-computer interfaces and neuromodulation, helping advance brain-computer technology toward a clearer, more implementable new phase. This edition of Yunqi Capital takes you inside the details.

➤ ➤ Yunqi Capital's Investment Perspective

"As a long-term investor deeply rooted in technology, Yunqi Capital has been consistently tracking frontier fields including brain-computer interfaces and brain-science AI infrastructure. Driven by ongoing advances in deep learning and AI, the precision and efficacy of neuromodulation are improving significantly. We are bullish on the Kongshanci team's execution capability and long-term vision in technology integration and clinical translation, and look forward to their accelerating the deployment of non-invasive brain-computer interface technology for more precise, convenient, and scalable applications in the mental health field."

The following content is adapted from VB Data (动脉网)

Proceeds from this round will primarily fund core technology R&D, clinical translation, and global expansion.

As a new-generation full-stack technology platform addressing brain science needs, Kongshanci Technology applies multi-dimensional brain signal parsing capabilities to ultrasound, magnetic, electrical, and optical modulation modalities, while deeply integrating AI across the entire diagnosis, treatment, and management workflow. This creates a technology flywheel of continuous iteration between clinical data and intervention protocols, delivering systematic solutions for diagnosing and treating brain function disorders.

On the clinical front, Kongshanci Technology has established deep research partnerships with the National Center for Mental Disorders, achieving breakthrough progress in early clinical exploration: significant symptom improvement within short treatment cycles, demonstrating the rare combination of high efficacy and leading potential in the non-invasive brain-computer interface space — work that has also garnered attention and recognition from top overseas institutions.

Following a "research — clinic — home" technology deployment path, the company is building out a product matrix covering diverse scenarios, committed to providing patients and users with brain science solutions that combine clinical value with technological leadership.

The completion of this financing round marks capital markets' strong recognition of Kongshanci Technology's technical moat and clinical value. With Yunqi Capital's support, the team will accelerate technology iteration and clinical translation while continuously strengthening its core competitive barriers.

We look forward to the company's continued deep cultivation of brain-computer interaction and neuromodulation, becoming a globally leading brain science intelligent infrastructure platform, and driving frontier technology from the laboratory into clinics and into homes!